Biosimilar Diplomacy By Other Means: GPhA CEO Calls Out Amgen Guest
This article was originally published in The Pink Sheet Daily
Executive Summary
During speech to the group’s annual meeting, GPhA President Ralph Neas says he is disappointed that Amgen, which is among the firms attending the gathering, is pushing biosimilar substitution restrictions in state legislatures.